» Articles » PMID: 33777790

Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective

Overview
Journal Front Oncol
Specialty Oncology
Date 2021 Mar 29
PMID 33777790
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The use process for chimeric antigen receptor T (CAR-T) cell drugs is complex and has been associated with a number of potentially severe complications, which requires management by a multidisciplinary team. Pharmacists are a key element in the team and have roles and responsibilities. Our objective was to develop a structured and practical guide that supports hospital pharmacist responsibilities and defines specific activities in a CAR-T cell therapy program, specifically in Europe.

Methods: A literature review was performed, and the recommendations related to pharmacy practice in CAR-T therapy programs were analyzed. A multidisciplinary team was assembled, and meetings were held to address the key tasks in the CAR-T cells' management process and to create the guide, based on national and international recommendations and in expert's opinions.

Results: The multidisciplinary team defined the following key tasks and issued recommendations to improve patient safety, treatment efficacy, and quality: patient selection and evaluation, CAR-T cell drug order to manufacturer, apheresis and material shipment, reception of CAR-T cell drug and storing, CAR-T cell drug prescription and pharmacy verification, CAR-T cell drug thawing and dispensing, CAR-T cell drug administration, patient education, pharmacovigilance and monitoring and outcomes' record and evaluation. In each task the pharmacist's role and how it can improve patient care are defined. A checklist was created to guarantee the compliance of standard operating procedures approved in the institution to manage CAR-T cell therapy and as a tool to collect required data for outcomes' record and evaluation.

Conclusion: This article provides a consensus set of safety recommendations regarding CAR-T therapy management in clinical practice, easily implementable by other institutions in the European setting. The guide identifies key steps where the involvement of hospital pharmacists would improve the safety and quality of the process and is a support guide to standardize hospital pharmacists' responsibilities within the multidisciplinary team.

Citing Articles

The role of hospital pharmacists in supporting the appropriate and safe use of CGT/ATMPs: a scoping review of current insights.

Shi J, Chen X, Hu H, Ung C BMC Health Serv Res. 2025; 25(1):52.

PMID: 39789612 PMC: 11721208. DOI: 10.1186/s12913-024-12026-4.


How to optimize the CAR-T Cell therapy process? A group concept mapping analysis of preconditions for a frictionless process from a German multistakeholder perspective.

Siefen A, Kurte M, Jakobs F, Teichert M, von Tresckow B, Reinhardt H Front Oncol. 2024; 14:1466803.

PMID: 39376984 PMC: 11456517. DOI: 10.3389/fonc.2024.1466803.


Cellular therapy site-preparedness: Inpatient pharmacy implementation at a large academic medical center.

Martino J, McConnell K, Greathouse L, Rosario B, Jaskowiak J J Oncol Pharm Pract. 2024; 30(8):1442-1449.

PMID: 39194372 PMC: 11590386. DOI: 10.1177/10781552241279025.


Innovation in BCMA CAR-T therapy: Building beyond the Model T.

Banerjee R, Lee S, Cowan A Front Oncol. 2022; 12:1070353.

PMID: 36505779 PMC: 9729952. DOI: 10.3389/fonc.2022.1070353.


Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy.

Ferreros P, Trapero I Diseases. 2022; 10(3).

PMID: 35892735 PMC: 9326641. DOI: 10.3390/diseases10030041.


References
1.
Ceschi A, Noseda R, Palin K, Verhamme K . Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database. Front Pharmacol. 2020; 11:557. PMC: 7212758. DOI: 10.3389/fphar.2020.00557. View

2.
. ASHP Statement on the Pharmacist's Role in Clinical Informatics. Am J Health Syst Pharm. 2016; 73(6):410-3. DOI: 10.2146/ajhp150540. View

3.
Clemmons A, Alexander M, DeGregory K, Kennedy L . The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group. Biol Blood Marrow Transplant. 2018; 24(5):914-922. DOI: 10.1016/j.bbmt.2017.12.803. View

4.
Maus M, Nikiforow S . The Why, what, and How of the New FACT standards for immune effector cells. J Immunother Cancer. 2017; 5:36. PMC: 5394615. DOI: 10.1186/s40425-017-0239-0. View

5.
Newman M, Benani D . A review of blinatumomab, a novel immunotherapy. J Oncol Pharm Pract. 2015; 22(4):639-45. DOI: 10.1177/1078155215618770. View